Precigen Stock News

Precigen Inc (PGEN) shares closed 1.8% lower than its previous 52 week low, giving the company a market cap of $671M. The stock is currently down 12.4% year-to-date, down 66.0% over the past 12 months, and down 87.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 37.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 30.5% The company's stock price performance over the past 12 months lags the peer average by 615.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Precigen Inc (PGEN) shares closed today 10.5% lower than it did at the end of yesterday. The stock is currently down 12.4% year-to-date, down 66.0% over the past 12 months, and down 87.4% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $4.00 and as low as $3.25 this week.Shares closed 68.2% below its 52-week high and 0.0% below its 52-week low.Trading volume this week was 83.4% higher than the 10-day average and 83.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 91.0% The company's stock price performance over the past 12 months lags the peer average by 935.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Precigen Inc (NASDAQ: PGEN) presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

GERMANTOWN, Md., Oct. 12, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

GERMANTOWN, Md., Oct. 1, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsid

GERMANTOWN, Md., Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2021 Results - Earnings Call Transcript

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 16.67% and 49.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 61.54% year over year to ($0.10), which beat th

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D). Results were